P. Clingan
About
P. Clingan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, P. Clingan has authored 29 papers receiving a total of 758 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in P. Clingan's work include Colorectal Cancer Treatments and Studies (12 papers), Gastric Cancer Management and Outcomes (9 papers) and Cancer Treatment and Pharmacology (5 papers). P. Clingan is often cited by papers focused on Colorectal Cancer Treatments and Studies (12 papers), Gastric Cancer Management and Outcomes (9 papers) and Cancer Treatment and Pharmacology (5 papers). P. Clingan collaborates with scholars based in Australia, United States and United Kingdom. P. Clingan's co-authors include David L. Morris, Josep Tabernero, Julie King, C. Boni, Thierry André, Tamas Hickish, Matilde Navarro, Andrea Bonetti, C. Topham and Armand de Gramont and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.
In The Last Decade
P. Clingan
29 papers receiving 735 citations
Peers
P. Clingan
A. Wein Germany
P. Comella Italy
Monica Lencioni Italy
Karl H. Link Germany
Hideki Ueno Japan
Michele Basso Italy
K C Lakshmaiah India
Nicola Borsellino Italy
Kristen Spencer United States
J. Wals Netherlands
Citations per year, relative to P. Clingan P. Clingan (= 1×)
peers
A. Wein
Countries citing papers authored by P. Clingan
Since
Specialization
Citations
This map shows the geographic impact of P. Clingan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Clingan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Clingan more than expected).
Fields of papers citing papers by P. Clingan
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by P. Clingan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Clingan. The network helps show where P. Clingan may publish in the future.
Co-authorship network of co-authors of P. Clingan
This figure shows the co-authorship network connecting the top 25 collaborators of P. Clingan. A scholar is included among the top collaborators of P. Clingan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Clingan. P. Clingan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Clingan, P., Daniel Brungs, Rahul Ladwa, et al.. (2020). 1084P Cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma (mCSCC): Preliminary safety and efficacy results from a phase I clinical trial. Annals of Oncology. 31. S736–S736.
2.
Sriuranpong, Virote, Özden Altundağ, P. Clingan, et al.. (2018). EMPOWER-lung 1: A randomized, open-label, multi-national, phase III trial of cemiplimab, a human PD-1 monoclonal antibody, versus chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 ≥50%. Annals of Oncology. 29. x37–x38.
3.
Lonardi, Sara, Takayuki Yoshino, Radka Obermannová, et al.. (2016). Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer. Annals of Oncology. 27. iv40–iv40.
4.
Chiorean, E. Gabriela, Daniel D. Von Hoff, Michele Reni, et al.. (2016). CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Annals of Oncology. 27(4). 654–660.
5.
Obermannová, Radka, Eric Van Cutsem, Takayuki Yoshino, et al.. (2016). Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. Annals of Oncology. 27(11). 2082–2089.
6.
Wilke, H., P. Clingan, G. Kurteva, et al.. (2014). Rainbow: A Global, Phase 3, Double-Blind Study of Ramucirumab Plus Paclitaxel Versus Placebo Plus Paclitaxel in the Treatment of Gastric Cancer Following Disease Progression: Western Population Subgroup. Annals of Oncology. 25. ii106–ii106.
7.
Pavlakis, Nick, et al.. (2012). A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer. Oncology Reports. 28(3). 763–767.
8.
Pawel, Joachim von, Robert M. Jotte, Eugene Paschold, et al.. (2012). Randomized phase 3 trial of amrubicin versus topotecan as second-line treatment for small cell lung cancer (SCLC). Pneumologie. 66(S 01).
9.
Jotte, Robert M., Joachim von Pawel, David R. Spigel, et al.. (2011). Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).. Journal of Clinical Oncology. 29(15_suppl). 7000–7000.
10.
Tournigand, Christophe, Thierry André, Jean‐Baptiste Bachet, et al.. (2010). FOLFOX4 as adjuvant therapy in elderly patients (pts) with colon cancer (CC): Subgroup analysis of the MOSAIC trial.. Journal of Clinical Oncology. 28(15_suppl). 3522–3522.
11.
Cunningham, David, Bhawna Sirohi, A Płużańska, et al.. (2008). Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Annals of Oncology. 20(2). 244–250.
12.
Tyndall, Joel D. A., Michael J. Kelso, P. Clingan, & Marie Ranson. (2008). Peptides and Small Molecules Targeting the Plasminogen Activation System: Towards Prophylactic Anti-Metastasis Drugs for Breast Cancer. Recent Patents on Anti-Cancer Drug Discovery. 3(1). 1–13.
13.
Gramont, Armand de, C. Boni, Matilde Navarro, et al.. (2007). Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. Journal of Clinical Oncology. 25(18_suppl). 4007–4007.
14.
Gramont, Armand de, C. Boni, Matilde Navarro, et al.. (2005). Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: Efficacy results with a median follow-up of 4 years. Journal of Clinical Oncology. 23(16_suppl). 3501–3501.
15.
Steinke, Karin, Derek Glenn, Julie King, et al.. (2004). Percutaneous Imaging–Guided Radiofrequency Ablation in Patients With Colorectal Pulmonary Metastases: 1-Year Follow-Up. Annals of Surgical Oncology. 11(2). 207–212.
16.
King, Julie, Jing Zhao, P. Clingan, & David L. Morris. (2003). Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects.. PubMed. 23(1B). 639–45.
17.
Olver, Ian, Paul Craft, P. Clingan, et al.. (1996). An open multicentre study of tropisetron for cisplatin‐induced nausea and vomiting. The Medical Journal of Australia. 164(6). 337–340.
18.
King, Jonathan, et al.. (1994). CEA REDUCTION AFTER CRYOTHERAPY FOR LIVER METASTASES FROM COLON CANCER PREDICTS SURVIVAL. Australian and New Zealand Journal of Surgery. 64(9). 612–614.
19.
Hamilton, C.S., et al.. (1990). Breast Appearance and Function After Breast Conserving Surgery and Radiotherapy. Acta Oncologica. 29(3). 291–295.
20.
Hamilton, C.S., et al.. (1990). Results of Breast Conserving Treatment of Breast Cancer. Acta Oncologica. 29(2). 137–142.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by A. Wein Breakdown of academic impact, for papers by P. Comella Breakdown of academic impact, for papers by Monica Lencioni Breakdown of academic impact, for papers by Karl H. Link Breakdown of academic impact, for papers by Hideki Ueno Breakdown of academic impact, for papers by Michele Basso Breakdown of academic impact, for papers by K C Lakshmaiah Breakdown of academic impact, for papers by Nicola Borsellino Breakdown of academic impact, for papers by Kristen Spencer Breakdown of academic impact, for papers by J. Wals